Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Recommendation of Buy by Brokerages

Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) has received an average recommendation of “Buy” from the nine ratings firms that are presently covering the firm, MarketBeat Ratings reports. Nine analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have updated their coverage on the stock […]

Related Keywords

China ,Canada ,Steven Gannon ,Sherrington Robin ,Xenon Pharmaceuticals Stock Performance ,Cantor Fitzgerald ,Financial Services Group Inc ,Nasdaq ,Capital Partners ,News Ratings For Xenon Pharmaceuticals Daily ,Analyst Recommendations For Xenon Pharmaceuticals ,Citigroup ,Tower Research Capital ,Xenon Pharmaceuticals Inc ,Insider Activity At Xenon Pharmaceuticals ,Institutional Trading Of Xenon Pharmaceuticals ,China Universal Asset Management Co ,Royal Bank ,Needham Company ,Xenon Pharmaceuticals ,Get Free Report ,Marketbeat Ratings ,Director Steven Gannon ,Research Capital ,Universal Asset Management ,Services Group ,Get Free ,Pharmaceuticals Inc ,Xenon Pharmaceuticals Daily ,